Pfizer Inc., the world’s biggest drugmaker, is diverting drug studies and tests from Japan as part of an industry push to avoid this nation’s regulatory delays and higher costs.

The New York-based maker of Lipitor, the No. 1 cholesterol medicine in the world, is increasing development spending in South Korea, said Akihisa Harada, head of clinical research at Pfizer’s local unit in Tokyo.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.